AstraZeneca Announces First Presentation Of Pivotal SEROQUEL XR(TM) Bipolar Studies
Apr 17th 2008Drug InformationBipolar
New pivotal trial data from two clinical studies with SEROQUEL XR? (quetiapine fumarate) once daily Extended Release Tablets were presented today at the Eighth International Review of Bipolar Disorder (IRBD) Conference in Copenhagen, Denmark.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
